scholarly journals SHORT AND LONG-TERM OUTCOMES OF DIFFERENT REVASCULARIZATION STRATEGIES IN PATIENTS WITH END STAGE RENAL DISEASE ON HEMODIALYSIS

2012 ◽  
Vol 59 (13) ◽  
pp. E549 ◽  
Author(s):  
Abel E. Moreyra ◽  
Peter Hynes ◽  
Yingzi Deng ◽  
Nora M. Cosgrove ◽  
Christopher Brown ◽  
...  
2011 ◽  
Vol 26 (9) ◽  
pp. 2965-2970 ◽  
Author(s):  
M. M. Sood ◽  
L. Miller ◽  
P. Komenda ◽  
M. Reslerova ◽  
J. Bueti ◽  
...  

2019 ◽  
Vol 8 (2) ◽  
pp. 29-29
Author(s):  
Jaiju James Chakola ◽  
Varun Mamidi ◽  
Vamsi Krishna Makkena ◽  
Jayakumar Matcha ◽  
Ramprasad Elumalai

2017 ◽  
Vol 37 (suppl_1) ◽  
Author(s):  
Dennis A Hopkinson ◽  
Samuel P Powell ◽  
Raveen Chawla ◽  
Wendy Bottinor ◽  
Jeremy S Turlington ◽  
...  

Background: Patients with diabetes may be at increased risk of contrast-induced nephropathy (CIN) when undergoing coronary and/or peripheral angiography or intervention but there is little data on long-term outcomes. We examined the relationship between diabetes, CIN and long-term outcomes in patients undergoing coronary and/or peripheral angiography and intervention. Methods and Results: We studied 4070 consecutive, predominantly (98%) male patients undergoing coronary and peripheral angiography and intervention and assessed the association between diabetes, CIN and long-term outcomes including renal dysfunction at 3 months, the need for dialysis and mortality. The mean age of the patients was 66.6 years. Approximately two fifths of the patients (n=1671, 41.05%) were diabetic. Patients with diabetes were the same age but had higher baseline creatinine compared to the patients without diabetes. CIN occurred in 70 (4.19%) diabetic patients and in 64 (2.67%) patients without diabetes at 72 hours after the procedure (odds ratio [OR] 1.59; 95% confidence interval [CI] 1.13 - 2.25; P=0.008). At 3 months, renal dysfunction was seen in 179 (10.71%) diabetic patients versus 174 (7.25%) of the non-diabetic group (OR 1.53, CI 1.23 - 1.91; P=0.0001). After a follow-up of 5 years, 31 (1.86 %) patients with diabetes had developed end-stage renal disease and were started on dialysis versus 13 (0.54 %) of the non-diabetic group (OR 3.47, CI 1.81 - 6.65; P<0.0001). 478 (28.61 %) patients of the diabetic group had died versus 479 (19.97 %) of the non-diabetic group (OR 1.61, CI 1.39 - 1.86; P<0.0001). On multivariate analysis, after adjustment for age, comorbidities, medical therapy and baseline creatinine, the presence of diabetes was significantly associated with CIN (OR 1.50, CI 1.06 - 2.43: p=0.02) and was significantly associated with the incidence of end stage renal disease requiring dialysis (OR 3.64, CI 2.07-10.04; P<0.0001) and with mortality at 5 years (OR 1.58, CI 1.42-2.03, P<0.0001). Conclusion: In this cohort of patients undergoing coronary and/or peripheral angiography and intervention diabetes was associated with CIN, with end-stage renal disease and the need for hemodialysis and was associated with an increased mortality.


2015 ◽  
Vol 62 (3) ◽  
pp. 804 ◽  
Author(s):  
Isibor Arhuidese ◽  
Tammam Obeid ◽  
Caitlin Hicks ◽  
Umair Qazi ◽  
Dorry Segev ◽  
...  

Author(s):  
Takuya Ogami ◽  
Paul Kurlansky ◽  
Hiroo Takayama ◽  
Yuming Ning ◽  
Ziad A. Ali ◽  
...  

Background Aortic stenosis is prevalent in end‐stage renal disease. Transcatheter aortic valve replacement (TAVR) is a plausible alternative for surgical aortic valve replacement. However, little is known regarding long‐term outcomes in patients with end‐stage renal disease who undergo TAVR. Methods and Results We identified all patients with end‐stage renal disease who underwent TAVR from 2011 through 2016 using the United States Renal Data System. The primary end point was 5‐year mortality after TAVR. Factors associated with 1‐ and 5‐year mortality were analyzed. A total of 3883 TAVRs were performed for patients with end‐stage renal disease. Mortality was 5.8%, 43.7%, and 88.8% at 30 days, 1 year, and 5 years, respectively. Case volumes increased rapidly from 17 in 2011 to 1495 in 2016. Thirty‐day mortality demonstrated a dramatic reduction from 11.1% in 2012 to 2.5% in 2016 ( P =0.01). Age 75 or older (hazard ratio [HR], 1.14; 95% CI, 1.05–1.23 [ P =0.002]), body mass index <25 (HR, 1.18; 95% CI, 1.08–1.28 [ P <0.001]), chronic obstructive pulmonary disease (HR, 1.25; 95% CI, 1.1–1.35 [ P <0.001]), diabetes mellitus as the cause of dialysis (HR, 1.22; 95% CI, 1.11–1.35 [ P <0.001]), hypertension as the cause of dialysis (HR, 1.17; 95% CI, 1.06–1.29 [ P =0.004]), and White race (HR, 1.17; 95% CI, 1.06–1.3 [ P =0.002]) were independently associated with 5‐year mortality. Conclusions Short‐term outcomes of TAVR in patients with end‐stage renal disease have improved significantly. However, long‐term mortality of patients on dialysis remains high.


Sign in / Sign up

Export Citation Format

Share Document